Gapping up
In reaction to earnings/guidance:
- LAD +5.3%, ASML +5.2%, WTFC +3.7%, ANTM +3.7%, HCSG +3.6%, LRN +3%, MTB +2.9%, IBM +2.4%, LULU +2.2% (5-yr outlook/guidance), PG +1.6%, MATX +1.5%, OMC +1.5%, NDAQ +1%
Other news:
- ALVR +20.7% (announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy posoleucel)
- IMAB +11% (report that the company is considering sale)
- HGEN +4.4% (Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS)
- GTE +4.1% (announces corporate update)
- VSCO +3% (launches Happy Nation brand for tweens)
- BODY +2.2% (CFO to depart)
Analyst comments:
- LZ +2.4% (upgraded to Buy from Neutral at Citigroup)
- EXC +1.5% (upgraded to Overweight from Neutral at JP Morgan)
- ABNB +1% (upgraded to Buy from Neutral at Citigroup)
- CAR +1% (upgraded to Equal Weight from Underweight at Barclays)